Hypericin - Soligenix

Drug Profile

Hypericin - Soligenix

Alternative Names: SGX 301; VIMRxyn

Latest Information Update: 27 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator New York University; Weizmann Institute of Science
  • Developer Soligenix
  • Class Anthraquinones; Anti-inflammatories; Antidepressants; Antipsoriatics; Antivirals; Cytostatics; Diagnostic agents; Perylenes; Polycyclic compounds; Radiation-sensitising agents; Small molecules
  • Mechanism of Action Cell death stimulants; Photosensitisers; Singlet oxygen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cutaneous T cell lymphoma
  • Discontinued Glioma; Hepatitis C; HIV infections; Hyperhidrosis; Kaposi's sarcoma; Psoriasis

Most Recent Events

  • 22 Aug 2018 Soligenix has patent protection for Hypericin in USA
  • 18 Sep 2017 Soligenix receives SBIR grant from National Cancer Institute for Hypericin development in Cutaneous T-cell lymphoma
  • 22 Feb 2017 Soligenix receives patent allowance for Hypericin in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top